

VT

PATENTES

BIOTECNOLOGÍA SANITARIA

Degeneración macular
Diabetes
Sistema nervioso
Sistema inmune

34



**Vigilancia
Tecnológica**
4º trimestre 2021

NIPO: 116-19-008-3

Este Boletín de Vigilancia Tecnológica en Biotecnología aplicada al sector sanitario surge del trabajo conjunto entre la Oficina Española de Patentes y Marcas (OEPM) y ASEBIO como miembro de la Plataforma Tecnológica Española de Mercados Biotecnológicos, y se encuadra dentro de una de las actividades de colaboración que la OEPM viene llevando a cabo con las referidas Plataformas para hacer llegar a las empresas, investigadores, y organizaciones que las integran una selección de las patentes más recientemente publicadas en determinados sectores tecnológicos.

Estos Boletines trimestrales, como el resto de los elaborados por la OEPM, ofrecen una información puntual, esquemática y de rápida lectura sobre una selección de las últimas patentes biotecnológicas publicadas en el

mundo relativas a cuatro líneas de investigación concretas: Sistema Nervioso, Sistema Inmune, Diabetes y Degeneración Macular. A través del número de publicación de cada patente, un enlace permite consultar el documento completo e incluso poder disponer de una traducción de la descripción realizada con la herramienta Patent translate.


También incluyen noticias sobre actividades realizadas por la OEPM que puedan resultar de interés a los usuarios. Si se desea recibir este Boletín periódicamente basta con cumplimentar el correspondiente [formulario de suscripción](#).

Se puede acceder al listado de solicitudes de patentes analizadas pulsando sobre las imágenes que aparecen a continuación.


Contenido




**DEGENERACIÓN
MACULAR**



DIABETES



SISTEMA NERVIOSO



SISTEMA INMUNE

Degeneración Macular

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2021241802	OLIX PHARMACEUTICALS INC [KR]	RNAi agent targeting connective tissue growth factor and use thereof
WO2021241803	OLIX PHARMACEUTICALS INC [KR]	RNAi agent targeting MyD88 and use thereof
WO2021243058	EMENDOBIO INC [US]; EMMANUEL RAFI [IL]; GOLAN MASHIACH MICHAL [IL]	Biallelic knockout of SARM1
WO2021225431	LOH HUI LING [MY]	Novel pharmaceutical composition and use thereof for repairing damaged retina and treating visual lesion
WO2021224679	GENOFOCUS INC [KR]	Compositions comprising enzymes and probiotics, and methods for preventing or treating macular degeneration
WO2021222654	SALIOGEN THERAPEUTICS INC [US]	Compositions and methods for treatment of inherited macular degeneration
WO2021216548	UNIV MASSACHUSETTS [US]	Methods and compositions for treatment of age-related macular degeneration
WO2021243203	FUJIFILM CELLULAR DYNAMICS INC [US]; US HEALTH [US]	Bilayer of retinal pigmented epithelium and photoreceptors and use thereof
WO2021243256	FUJIFILM CELLULAR DYNAMICS INC [US]	Retinal pigmented epithelium and photoreceptor dual cell aggregates and methods of use thereof
WO2021226444	REGENERON PHARMA [US]	VEGF traps and mini-traps and methods for treating ocular disorders and cancer
WO2021224430	UNIV MANCHESTER [GB]	Detection of complement proteins
WO2021198369	PANDA JONAS SONGHOMITRA [DE]; UNIVERSITAET HEIDELBERG [DE]	Agents for use in the therapeutic or prophylactic treatment of retinal pigment epithelium associated diseases
WO2021178899	PANIGRAHI DIPAK [US]	Use of cannabanoids in the treatment of proliferative diabetic retinopathy

Diabetes

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2021246755	RESEARCH & BUSINESS FOUND SUNGKYUNKWAN UNIV [KR]	Composition, for preventing, alleviating or treating metabolic disease, comprising phospholipase D2 inhibitor
WO2021242021	AULBIO CO LTD [KR]	Controlled release microspheres containing glucagon-like peptide 1 agonist, and method for producing same
WO2021235881	UNIV YONSEI IACF [KR]	Biomarker comprising urine glycated albumin for diagnosis of diabetic nephropathy
WO2021227989	TIANJIN INSTITUTE OF PHARMACEUTICAL RES CO LTD [CN]	Polypeptide derivative having dual receptor agonistic action and use thereof
WO2021226447	HARVARD COLLEGE [US]; BRIGHAM & WOMENS HOSPITAL INC [US]	Methods for inducing bile acid sulfotransferase SULT2A for treating metabolic disorders
WO2021226112	ACCELERATED BIOSCIENCES CORP [US]	Mortal pluripotent stem cells
WO2021222491	UNIV INDIANA TRUSTEES [US]	Neurogenic tissue nanotransfection in the management of cutaneous diabetic polyneuropathy
WO2021221482	ONEGENE BIOTECHNOLOGY INC [KR]	Novel protein conjugate, and use thereof for preventing or treating nonalcoholic steatohepatitis, obesity and diabetes
WO2021218687	UNIV SOOCHOW [CN]	Stem cell drug for treating diabetes
WO2021220124	SINGH SHYAM SUNDER [IN]	A pharmaceutical composition and method of treatment using L-Carnosine and glutathione, its precursors or derivatives thereof
WO2021222297	UNIV CALIFORNIA [US]	Methods for generating thymic cells in vitro
WO2021215828	KOBIOLABS INC [KR]	Protein variant having GLP-1 inducing activity and use thereof
WO2021212026	INTARCIA THERAPEUTICS INC [US]	Long acting glucagon receptor selective peptides and methods of use
WO2021210872	SAMSUNG LIFE PUBLIC WELFARE FOUNDATION [KR]	Composition for preventing or treating diabetic skin disease, comprising exosome derived from thrombin-treated stem cell
WO2021209930	BIORCHESTRA CO LTD [KR]	SETD7 epigenetic modulators

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2021206523	BIONEER CORP [KR]; SIRNAGEN THERAPEUTICS CORP [KR]; UNIV SOONCHUNHYANG IND ACAD COOP FOUND [KR]	Composition using urine sample for diagnosis of kidney disease
WO2021201660	SEOUL NAT UNIV R&DB FOUNDATION [KR]	Cell capsulating layer, capsulated cells, cell capsulating composition and preparation method therefor
WO2021201516	APTAMER SCIENCES INC [KR]	Insulin receptor-specific aptamer and use thereof
WO2021195344	MASSACHUSETTS GEN HOSPITAL [US]	Compositions and methods for diabetes treatment
WO2021194110	UNIV INDUSTRY COOPERATION GROUP KYUNG HEE UNIV [KR]	Composition for preventing or treating metabolic diseases, containing Jujuboside A as active ingredient
WO2021193360	KANEKA CORP [JP]; NAT CENTER FOR GLOBAL HEALTH AND MEDICINE [JP]	Method for inducing differentiation into pancreatic α cells
WO2021195508	EPIVAX INC [US]	Tregitope constructs useful in the prevention and treatment of type 1 diabetes
ES2855228	UNIV VALLADOLID [ES]; UNIV AVEIRO [PT]	Procedimiento para el nanorecubrimiento celular y su inmunoaislamiento
WO2021188349	UNIV CALIFORNIA [US]	Methods of treating mitochondrial disorders
WO2021182901	UNIV YONSEI IACF [KR]	Composition for preventing or treating metabolic diseases, comprising tat peptide variant as active ingredient
WO2021179106	BEIJING SUNGEN BIOMEDICAL TECH CO LTD [CN]	Application of GP73 inhibitor in preparation of drug for treating diabetes
WO2021182928	SL METAGEN [KR]	Novel bispecific protein and use thereof
WO2021180047	BEIJING SUNGEN BIOMEDICAL TECH CO LTD [CN]	Use of GP73 inhibitor in preparation of medicine for treating diabetes
WO2021177473	MVEX JAPAN INC [JP]	Extracellular vesicle compositions and the use thereof in the treatment of skin conditions and in immune modulation
WO2021178417	THERMALIN INC [US]; UNIV CASE WESTERN RESERVE [US]	Compositions containing rapid-acting insulin analogues
WO2021169512	UNIV SUN YAT SEN [CN]	Polypeptide compound and application thereof in prevention or treatment of diabetes or diabetes complication
WO2021231898	OP T LLC [US]; UNIV COLORADO REGENTS [US]	Nanoparticle compositions and uses thereof
WO2021226551	ALPINE IMMUNE SCIENCES INC [US]	APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2021239815	UNIV AUTÒNOMA DE BARCELONA [ES]	Fibroblast growth factor 21 (FGF21) gene therapy for central nervous system disorders
WO2021209822	ABIONYX PHARMA SA [FR]	CER-001 therapy for treating kidney disease
WO2021212023	INTARCIA THERAPEUTICS INC [US]	Long acting peptide tyrosine tyrosine (PYY) analogs and methods of use
WO2021202824	ABBOTT LAB [US]	Bovine milk exosome products and methods, nutritional compositions, and therapeutic methods
WO2021202806	FINCH THERAPEUTICS HOLDINGS LLC [US]	Compositions comprising non-viable fecal microbiota and methods of use thereof
WO2021181436	UNIV DEGLI STUDI DI ROMA TOR VERGATA [IT]	Peroxiredoxin 6 or a synthetic analogue thereof for use as a hypoglycaemic agent
WO2021191483	UNIV VALLADOLID [ES]; UNIV AVEIRO [PT]	Method for cell nanocoating and immunoisolation
WO2021178899	PANIGRAHI DIPAK [US]	Use of cannabanoids in the treatment of proliferative diabetic retinopathy
WO2021195672	UNIV CALIFORNIA [US]	Detection and treatment of intestinal fibrosis

Sistema Nervioso

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2021242757	UNIV PENNSYLVANIA [US]	Monoclonal antibodies against pathological tau, and methods using same
WO2021236809	OTHAIR PROTHENA LTD [IE]; BARBOUR ROBIN [US]; KINNEY GENE [US]; ZAGO WAGNER [US]; NIJJAR TARLOCHAN S [US]	Multi-epitope vaccine for the treatment of Alzheimer's disease
WO2021228125	UNIV HONG KONG SCIENCE & TECH [CN]	Protein markers for assessing Alzheimer's disease
WO2021231887	UNIV FLORIDA [US]	Compositions and methods of detection of pre-symptomatic ALS
WO2021221485	ABION INC [KR]	Human interferon-beta variant with double mutation and method for improving stability of human interferon-beta variant
WO2021221784	UNIV FLORIDA [US]; GRYPHON BIO THERAPEUTICS INC	Circular bifunctional aptamers and trifunctional aptamers targeting tau
WO2021214720	BIORCHESTRA CO LTD [KR]	Diagnostic methods using miR-485-3p expression
WO2021216980	UNIV CORNELL [US]	Targeting the palmitoylation/depalmitoylation cycle to treat inflammatory diseases
WO2021216778	ALLEN INST [US]	Artificial expression constructs for selectively modulating gene expression in neocortical layer 5 glutamatergic neurons
WO2021211894	SHAPE THERAPEUTICS INC [US]	Targeted RNA editing using engineered adenosine deaminase acting on tRNA (ADAT) systems
WO2021211614	UNIV FLORIDA [US]	AAV-based gene therapies for treatment of autoimmune diseases
WO2021210798	AMYLOID SOLUTION INC [KR]; UNIV YONSEI IACF [KR]	Pharmaceutical composition for treating degenerative brain disease, including glycine transporter as active ingredient
WO2021210878	GWANGJU INST SCIENCE & TECH [KR]	CRBN-binding peptide and composition for preventing or treating Alzheimer's disease using same
WO2021210537	SHIMADZU CORP [JP]; UNIV OSAKA PUBLIC CORP [JP]	Differentiation peptide
WO2021207854	UNIV BRITISH COLUMBIA [CA]	Compositions and methods for inhibiting TDP-43 and FUS aggregation
WO2021205361	JANSSEN BIOTECH INC [US]	Anti-CD98 antibodies and uses thereof
WO2021202771	YOUNG BRUCE K [US]; CHAN MICHAEL K [US]	Compositions and methods utilizing amniotic fluid stem cells

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2021200940	FUJIREBIO KK [JP]	Method for immunoassay of amyloid β in blood, and kit for same
WO2021200259	ICHIMARU PHARCOS INC [JP]	VIPR2 antagonist peptide
WO2021195750	JEFFERIES WILFRED [CA]; SINGH CHAAHAT [CA]	Methods for treating Alzheimer's disease
WO2021195770	UNIV BRITISH COLUMBIA [CA]; PROMIS NEUROSCIENCES INC [CA]	Antibodies to misfolded amyloid beta
WO2021195431	BRIGHAM & WOMENS HOSPITAL INC [US]; GENERAL BIOPHYSICS LLC [US]; ILIN ILYA [US]; BUTOVSKY OLEG [US]	Inhaled xenon therapy in neurodegenerative disease
WO2021189355	CHINESE INSTITUTE FOR BRAIN RES BEIJING [CN]	Amino acid mediated gene delivery and its uses
WO2021190563	TALENGEN INT LTD [CN]	Method and medicine for treating Huntington's disease
WO2021190558	TALENGEN INT LTD [CN]	Method and drug for treating Alzheimer disease
WO2021186478	URVOGELBIO PRIVATE LTD [IN]	Biomarker panels, systems, and methods for risk stratification of a subject for Alzheimer's disease
WO2021184404	HANGZHOU XINGAO BIOTECHNOLOGY CO LTD [CN]	Composition of novel immune agonist compound and use thereof in medicine capable of resisting multiple diseases
WO2021187478	KANAGAWA INSTITUTE OF INDUSTRIAL SCIENCE AND TECH [JP]	Composition containing self-assembling peptide
WO2021188802	BROWN KATHLYNN C [US]; MCGUIRE MICHAEL [US]; VENUGOPAL INDU [US]	Molecular transport system to the central nervous system
WO2021188825	NERENBERG MICHAEL [US]; IBARRA ARKAITZ [US]; ZHUANG JIALI [US]; ACOSTA ALEXANDER [US]	Systems and methods of detecting a risk of Alzheimer's disease using a circulating-free mRNA profiling assay
WO2021187745	SAMSUNG LIFE PUBLIC WELFARE FOUNDATION [KR]; ENCELL CO LTD [KR]	Pharmaceutical composition, for preventing or treating Charcot-Marie-Tooth disorder, comprising mesenchymal stem cells or insulin secreted by mesenchymal stem cells
WO2021183502	THE METHODIST HOSPITAL SYSTEM [US]	Engineered nucleic acids and uses thereof
WO2021183554	UNIV KENTUCKY RES FOUND [US]	Manipulating glycogen in Alzheimer's disease, epilepsy, traumatic brain injury, and ALS as a treatment
WO2021180118	SHANGHAI BELIEF DELIVERY BIOMED CO LTD [CN]	Novel use of aspirin compound in increasing nucleic acid expression
WO2021178448	MOTOR LIFE SCIENCES LLC [US]; STENGER THOMAS CHARLES [US]; STENGER MARY LOUISE [US]	Compositions and methods for diagnosing, preventing, and treating amyotrophic lateral sclerosis in patients with hypofunctional anti-trypsin activity
WO2021159093	UNIV SOUTH FLORIDA [US]	Inhibition of beta-arrestin oligomerization in tauopathy
WO2021242909	SHAPE THERAPEUTICS INC [US]	High throughput engineering of functional AAV capsids

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2021229461	CONSIGLIO NAZIONALE RICERCHE [IT]	Myelin nanovesicles and uses thereof
WO2021226551	ALPINE IMMUNE SCIENCES INC [US]	APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof
WO2021231579	UNIV PENNSYLVANIA [US]	Compositions for DRG-specific reduction of transgene expression
WO2021245092	UNIV DEL PAIS VASCO EUSKAL HERRIKO UNIBERSITATEA [ES]; ADMINISTRACION GENERAL DE LA COMUNIDAD AUTONOMA DE EUSKADI [ES]; FUNDACIO INST DINVESTIGACIO BIOMEDICA DE BELLVITGE IDIBELL [ES]	In vitro methods for the prognosis of amyotrophic lateral sclerosis
WO2021231204	GENENTECH INC [US]	Complement component 4 inhibitors for treating neurological diseases, and related compositons, systems and methods of using same
WO2021234607	ST JUDE CHILDRENS RES HOSPITAL [US]	Detection of Alzheimer's disease using specific biomarkers
WO2021239956	GENEURO SA [CH]; FONDAMENTAL [FR]	Anti-HERV-W envelope protein antibody for use in the treatment of psychotic diseases
WO2021233901	RRW B V [NL]; VAN DE WIEL FREDERIKUS GERARDUS JOSEPHUS MARIA [NL]	Probiotic bacteria for treating Alzheimer's disease
WO2021222168	SOLA BIOSCIENCES LLC [US]	Compositions and methods for the treatment of TDP-43 proteinopathies
WO2021202777	GENENTECH INC [US]	Uses of tau phosphosites as biomarkers for Alzheimer's disease
WO2021202509	ETERNITY BIOSCIENCE INC [US]	Treatment of Alzheimer's disease
WO2021198698	UNIV OXFORD INNOVATION LTD [GB]	Method for diagnosing a condition characterized by TDP-43 proteinopathy
WO2021201710	INST DE MEDICINA MOLECULAR JOAO LOBO ANTUNES [PT]; UNIV DE COIMBRA [PT]; FACULDADE DE MEDICINA DA UNIV DE LISBOA [PT]	Therapeutic agents, pharmaceutical compositions, and associated biomarkers based on Trk-B
WO2021181268	UNIV DEGLI STUDI MILANO [IT]; UNIV POLITECNICA DELLE MARCHE [IT]	ADAM10 endocytosis inhibitor peptides and related uses for the treatment of Alzheimer's disease
WO2021205010	INST NAT SANTE RECH MED [FR]; UNIV STRASBOURG [FR]	Nucleic acids encoding human FUS protein and use in the treatment of amyotrophic lateral sclerosis (ALS)
WO2021204994	NOVARTIS AG [CH]	Ofatumumab for treating MS while maintaining serum IgG
WO2021184020	CODIAK BIOSCIENCES INC [US]	Methods of treating neuroinflammation
WO2021180782	LIFEARC [GB]; GEORG AUGUST UNIV GOETTINGEN STIFTUNG OEFFENTLICHEN RECHTS UNIVSMEDIZIN [DE]	Cyclic peptides
WO2021173471	LILLY CO ELI [US]	Anti-human CD19 antibodies

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2021242903	SHAPE THERAPEUTICS INC [US]; BRIGGS ADRIAN [US]; BOOTH BRIAN [US]	Compositions and methods for modifying target RNAs
WO2021226112	ACCELERATED BIOSCIENCES CORP [US]	Mortal pluripotent stem cells
WO2021222491	UNIV INDIANA TRUSTEES [US]	Neurogenic tissue nanotransfection in the management of cutaneous diabetic polyneuropathy
WO2021194902	FLORICA THERAPEUTICS INC [US]	Neuronal diencephalon stem cells, preparation and uses for treatment and prevention of hormonal disorders and other diseases
WO2021188349	UNIV CALIFORNIA [US]	Methods of treating mitochondrial disorders
WO2021239815	UNIV AUTÒNOMA DE BARCELONA [ES]	Fibroblast growth factor 21 (FGF21) gene therapy for central nervous system disorders

Sistema Inmune

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2021246610	UNIV NAT CHONNAM IND FOUND [KR]	Composition for preventing or treating inflammatory diseases, comprising <i>Lactobacillus sakei</i> CVL-001 strain
WO2021246199	TOHO UNIV [JP]	Method for predicting therapeutic effect on psoriasis, method for evaluating candidate substance for treating psoriasis, and method and kit for evaluating disease state of psoriasis
WO2021245670	MEDICAL RES & DEVELOPMENT FUND FOR HEALTH SERVICES BNAI ZION MEDICAL CENTER [IL]; TECHNION RES & DEV FOUNDATION [IL]; THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIV OF OXFORD [GB]	Modified Semaphorin 3A, compositions comprising the same and uses thereof
WO2021247548	CEDARS SINAI MEDICAL CENTER [US]	Treatments for a sub-population of inflammatory bowel disease patients
WO2021233246	BIOSION INC [CN]	Antibodies binding IL6R and uses thereof
WO2021234699	UNIV RAMOT [IL]	MAdCAM-1 polypeptides and uses thereof
WO2021226695	FUNDACAO UNIV FEDERAL DO ABC UFABC [BR]; UNIV BRAUNSCHWEIG TECH [DE]	Recombinant human antibodies for inhibiting human tissue kallikrein 7 (KLK7) and use in diseases related to the process of skin desquamation
WO2021230705	PROGEN CO LTD [KR]	Novel recombinant fusion protein and use thereof
WO2021230393	KINE SCIENCES CO LTD [KR]	Peptide for treating inflammatory skin diseases and use thereof
WO2021230581	ASAN FOUND [KR]; UNIV ULSAN FOUND IND COOP [KR]	Discovery of novel Akkermansia muciniphila AK32 and application thereof for prevention or treatment of intestinal injury
WO2021224823	JANSSEN BIOTECH INC [US]	Methods of treating Crohn's disease with anti-IL23 specific antibody
WO2021222806	ICAHN SCHOOL MED MOUNT SINAI [US]; GOVERNING COUNCIL UNIV TORONTO [CA]	Compositions and methods for preventing, detecting, and treating inflammatory bowel disease
WO2021221471	UNIV KONKUK IND COOP CORP [KR]	Method for producing extracellular vesicles from three-dimensionally cultured stem cells

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2021218953	SHANGHAI PUREMAB BIO TECH CO LTD [CN]	Antibody against human complement protein (C5) and application thereof
WO2021216980	UNIV CORNELL [US]	Targeting the palmitoylation/depalmitoylation cycle to treat inflammatory diseases
WO2021216899	KINDRED BIOSCIENCES INC [US]	IL4/IL13 receptor molecules for veterinary use
WO2021217145	CHILDRENS HOSPITAL PHILADELPHIA [US]	Compositions and methods for regulation of cell activity via modulation of beta-cytokine activity
WO2021216810	KINDRED BIOSCIENCES INC [US]	Long-acting anti-IL31 antibodies for veterinary use
WO2021216458	GENZYME CORP [US]	Humanized anti-complement factor Bb antibodies and uses thereof
WO2021211614	UNIV FLORIDA [US]	AAV-based gene therapies for treatment of autoimmune diseases
WO2021207466	CREDO SCIENCE LLC [US]	Diagnosing and treating fibromyalgia
WO2021199046	BIOND BIOLOGICS LTD [IL]	Immunomodulatory compositions and use thereof
WO2021202457	EXAGEN INC [US]	Cardiovascular biomarkers for systemic lupus erythematosus
WO2021201271	UNIV MIYAZAKI [JP]	Novel adrenomedullin analog, method for producing the same, and pharmaceutical use thereof
WO2021201260	STEMRIM INC [JP]; UNIV OSAKA [JP]	Peptide having mesenchymal stem cell mobilizing activity
WO2021201276	MEDRX CO LTD [JP]	Double-stranded RNA specifically inhibiting expression of IL-23, and pharmaceutical composition including same
WO2021195703	SERVATUS LTD [AU]	Combination therapy for inflammatory bowel disease
WO2021195636	UNIV CORNELL [US]	Microbiome-based therapeutics
WO2021194294	CATHOLIC UNIV KOREA IND ACADEMIC COOPERATION FOUNDATION [KR]	Avatar model platform for evaluating autoimmune diseases
WO2021194281	KOREA RES INST BIOSCIENCE & BIOTECHNOLOGY [KR]; SEOUL NAT UNIV R&DB FOUNDATION [KR]	TARS derived from <i>Akkermansia muciniphila</i> or fragment thereof, and use thereof
WO2021195672	UNIV CALIFORNIA [US]	Detection and treatment of intestinal fibrosis
WO2021188631	KINDRED BIOSCIENCES INC [US]	Anti-IL4 receptor antibodies for veterinary use
WO2021184060	PROTEOMICS INT PTY LTD [AU]	Endometriosis biomarkers
WO2021184080	UNIV MONASH [AU]	Compositions and methods for treating lupus

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2021172900	GI BIOME [KR]; MADIOGEN CO LTD [KR]	<i>Lactobacillus helveticus</i> strain and composition containing same for prevention or treatment of inflammatory diseases
WO2021161270	JANSSEN BIOTECH INC [US]	Safe and effective method of treating ulcerative colitis with anti-IL-12/IL23 antibody
WO2021159068	NCH CORPORTION [US] NCH CORP [US]	Composition and method of using germinative compounds in probiotics for inflammation reduction in humans
WO2021242903	SHAPE THERAPEUTICS INC [US]; BRIGGS ADRIAN [US]; BOOTH BRIAN [US]	Compositions and methods for modifying target RNAs
WO2021242663	BOEHRINGER INGELHEIM INT [DE]	Anti-PD-1 antibodies
WO2021231898	OP T LLC [US]; UNIV COLORADO REGENTS [US]	Nanoparticle compositions and uses thereof
WO2021240436	SANOFI BIOTECHNOLOGY [FR]	Compositions and methods for treating noninflammatory pain in subjects with rheumatoid arthritis
WO2021240369	SANOFI BIOTECHNOLOGY [FR]; FEIST EUGEN [DE]; ARIES PEER MALTE [DE]; ZINE SILKE [DE]; BURKHARDT HARALD [DE]; TONEY HANS PETER [DE]	Compositions comprising an antibody against interleukin-6 receptor for the treatment of rheumatoid arthritis and methods of using same
WO2021234172	UNIV ULSTER [GB]	A genetic test to predict anti-TNF drug response
WO2021226591	ELECTRA THERAPEUTICS INC [US]	SIRP alpha, SIRP beta 1, and SIRP gamma antibodies and uses thereof
WO2021214548	NOGRA PHARMA LTD [IE]	Compositions of SMAD7 antisense oligonucleotides (ASO) and methods of using the same
WO2021228805	NESTLE SA [CH]	Methods and compositions using serpin producing bacteria
WO2021215919	POLPHARMA BIOLOGICS UTRECHT B V [NL]	Humanized anti-human CD89 antibodies and uses thereof
WO2021198707	UNIV OXFORD INNOVATION LTD [GB]	Antibodies
WO2021188591	PTM THERAPEUTICS INC [US]	Anti-glycan antibodies and uses thereof
WO2021183849	GENENTECH INC [US]	Anti-interleukin-33 antibodies and uses thereof
WO2021188374	NEOLEUKIN THERAPEUTICS INC [US]; UNIV WASHINGTON [US]	Interleukin-2 receptor beta (IL-2Rβ) binding polypeptides
EP3895713 A1	TZU CHI UNIV [TW]	Methods for mobilizing stem cells
WO2021178814	REGENERON PHARMA [US]	Anti-GITR antibodies and uses thereof

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2021191396	UNIV TOULOUSE 3 PAUL SABATIER [FR]; CT HOSPITALIER UNIVERSITAIRE TOULOUSE [FR]; INST NAT SANTE RECH MED [FR]; ASSIST PUBLIQUE HOPITAUX DE MARSEILLE [FR]; UNIV AIX MARSEILLE [FR]	Apheresis column for treating rheumatoid arthritis
WO2021181091	UNIV DUNDEE [GB]; INST NAT SANTE RECH MED [FR]; UNIV LILLE [FR]; CENTRE HOSPITALIER REGIONAL UNIV LILLE [FR]	IL-10 muteins
WO2021180851	MESOBLAST INT SARL [CH]	Method for treating inflammatory bowel disease II
WO2021180850	MESOBLAST INT SARL [CH]	Method for treating inflammatory bowel disease I
WO2021176090	SANOFI SA [FR]	Protease-processed molecules
WO2021175954	IMCHECK THERAPEUTICS SAS [FR]; INST NAT SANTE RECH MED [FR]; CENTRE NAT RECH SCIENT [FR]; INST JEAN PAOLI & IRENE CALMETTES [FR]; UNIV AIX MARSEILLE [FR]	Antibodies having specificity for BTNL8 and uses thereof
EP3909594	SORIA ESCOMS BERNAT [ES]	Mesenchymal stromal cells for the treatment of COVID-19 and other inflammatory, autoimmune and degenerative diseases
WO2021223079	CROPEDIT BIOTECHNOLOGY INC [CN]	Nano antibody and use thereof
WO2021221485	ABION INC [KR]	Human interferon-beta variant with double mutation and method for improving stability of human interferon-beta variant
WO2021201236	KYOWA KIRIN CO LTD [JP]	Antibody composition
WO2021184404	HANGZHOU XINGAO BIOTECHNOLOGY CO LTD [CN]	Composition of novel immune agonist compound and use thereof in medicine capable of resisting multiple diseases
WO2021231210	GENENTECH INC [US]	Complement component C1R inhibitors for treating a neurological disease, and related compositions, systems and methods of using same
WO2021231204	GENENTECH INC [US]	Complement component 4 inhibitors for treating neurological diseases, and related compositions, systems and methods of using same
WO2021216978	AZTHERAPIES INC [US]	Cellular ablation of HLA-class I MHC
WO2021202590	ALECTOR LLC [US]	Anti-merTK antibodies and methods of use thereof
WO2021202373	BAXALTA INC [US]; BAXALTA GMBH [CH]	A method to produce an immunoglobulin preparation from C-1 inhibitor depleted plasma
WO2021184020	CODIAK BIOSCIENCES INC [US]	Methods of treating neuroinflammation

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2021173471	LILLY CO ELI [US]	Anti-human CD19 antibodies
WO2021195508	EPIVAX INC [US]	Tregitope constructs useful in the prevention and treatment of type 1 diabetes
WO2021221472	MODNBIO INC CO LTD [KR]	Micelle particles comprising amphipathic ginsenoside, composition comprising same, and preparation method thereof

Noticias

“10 PATENTES ESPAÑOLAS QUE HAN HECHO HISTORIA”: EL NUEVO VIDEO REALIZADO POR "QUANTUM FRACTURE" Y PROMOCIONADO POR LA OEPM

La Oficina Española de Patentes y Marcas, O.A. (OEPM), en el marco de su Plan Estratégico,



busca promover de forma innovadora el uso de la Propiedad Industrial con la finalidad de transformar la sociedad basada en el conocimiento en generadora de valor y catalizadora de la transformación tecnológica e industrial de nuestro país.

Para ello, se ha lanzado recientemente un video promocionado por la OEPM en el conocido canal de YouTube Quantum Fracture, con José Luis Crespo a la cabeza, donde durante unos 16 minutos se realiza un recorrido histórico de las patentes a través de una cuidadosa selección de las mismas

con el fin de dar a conocer su utilidad y su importancia para promover de la innovación y el avance hacia una sociedad más innovadora a la vez que más justa y sostenible.

La elección de José Luis Crespo para conducir esta pieza audiovisual fue motivada por su formación en Física y su actividad como divulgador científico, lo que le conecta indirectamente con la base del mundo de las patentes. Su narración, unida a las animaciones sobre inventos que van desde el siglo XV hasta nuestros días, y a las entrevistas con inventores y personal de la OEPM: el Director de la OEPM, José Antonio Gil Celedonio, la Directora del Departamento de Patentes e Información Tecnológica, María José de Concepción y la responsable del Archivo Histórico de la OEPM, Ana Naseiro, hacen de este vídeo un instrumento eficaz de difusión que esperamos sea fructífero.

¡Esperamos que os guste tanto como a nosotros!

[Enlace al vídeo “10 Patentes Españolas que han hecho Historia”](#)

REELECCIÓN DE LEOPOLDO BELDA, JEFE DE ÁREA DE PATENTES DE MECÁNICA GENERAL Y CONSTRUCCIÓN, COMO PRESIDENTE DEL COMITÉ PERMANENTE DE DERECHO DE PATENTES DE LA OMPI EN LA SCP33

Por un año más nuestro compañero Leopoldo Belda Soriano (Jefe de área de patentes de mecánica general y construcción de la OEPM), fue reelegido Presidente del Comité Permanente de Derecho de Patentes de la Organización Mundial de la Propiedad Intelectual (OMPI).

Su reelección tuvo lugar en la celebración de la trigésimo tercera sesión del Comité Permanente de Derecho de Patentes (SCP por sus siglas en inglés) celebrada en la OMPI en Ginebra los pasados 6 y 9 de diciembre.

Además de su reelección, los debates giraron alrededor de los 5 temas habituales del Comité en los últimos años: Excepciones y limitaciones a los derechos de patentes, Calidad de las Patentes, Patentes y Salud, Confidencialidad en las comunicaciones entre agentes de patentes y clientes, y Transferencia de Tecnología.



Asimismo, destacaron las sesiones de intercambio de experiencias en relación con la utilización de la IA por las Oficinas de Patentes, donde se apreció que esta tecnología se está incorporando a un gran número de oficinas y las presentaciones en relación con las bases de acceso gratuito sobre la situación legal de las patentes sobre medicamentos y vacunas; Pat-informed, Medicines Patent Pool y el registro farmacéutico de la Organización Euroasiática de patentes. La OEPM participó con declaraciones y presentaciones en relación con el informe sobre el sistema internacional de patentes, la calidad de las patentes, la confidencialidad en las comunicaciones y la transferencia de tecnología.

[Más Información](#)

CAMPAÑA SENSIBILIZACIÓN FRENTE A FALSIFICACIONES OEPM 2021

La nueva campaña de sensibilización frente a la compra de productos falsificados este año busca



estimular la compra de productos originales. El pasado 26 de noviembre tuvo lugar el acto oficial de presentación por parte de la Ministra Reyes Maroto, acompañada del Presidente de la OEPM Pablo Garde y el Director de la misma, José Antonio Gil Celedonio. En sus intervenciones destacaron el compromiso

del Ministerio de Industria, Comercio y Turismo con la defensa de los derechos de propiedad industrial (DPI) y la lucha frente a su vulneración.

El objetivo de esta campaña es concienciar a los consumidores para que compren productos originales por los efectos secundarios positivos que conlleva: impulsa el comercio local, fomenta la innovación, protege el medio ambiente, reactiva la economía, cuida la salud, protege tus derechos como consumidor y genera empleo de calidad. Con el lema “Comprar productos originales, tiene efectos secundarios positivos” la campaña se difunde en medios de comunicación entre el 10 y el 20 de diciembre, coincidiendo con el pico anual de consumo en los hogares por la cercanía de Black Friday y Navidad.

La campaña estará presente en televisión, radio, prensa, internet, así como en redes sociales con la etiqueta #efectossecundarios.

En el siguiente enlace se encuentra el material de esta campaña, que se complementa con el spot que podrá visionar en la página web:

<https://stopfalsificaciones.oepm.es/index.html>

Esta campaña es uno de los Proyectos del Plan Estratégico 21-24 de la OEPM incluido dentro del Objetivo General 4: Impulsar la lucha contra la falsificación y la vulneración de los derechos de Propiedad Industrial (DPI).

[Más información](#)

